Diverticulitis after Fecal Microbiota Transplant for C. difficile Infection

Clostridium difficile Infection and Fecal Microbiota Transplant.

Clostridium difficile infection (CDI) is a major source of morbidity and mortality for hospitalized patients. Although most patients have a clinical response to existing antimicrobial therapies, recurrent infection develops in up to 30% of patients. Fecal microbiota transplant is a novel approach to this complex problem, with an efficacy rate of nearly 90% in the setting of multiple recurrent C...

Fecal microbiota transplant protocol for clostridium difficile infection.

Fecal microbiota transplant has become more acceptable as a therapeutic for recurrent Clostridium difficile infection. The FDA has an enforcement discretion policy for practitioner's performing this therapy, which includes informed consent for this experimental treatment. This manuscript describes a typical procedure that can be followed that includes the important aspects of this preparation a...

Weight Changes in Fecal Microbiota Transplant for Clostridium difficile

Is a Single Fecal Microbiota Transplant a Promising Treatment for Recurrent Clostridium difficile Infection?

Clostridium difficile infection, a common hospital-associated infection, is a gastrointestinal illness that becomes recurrent in about 25% of infected patients. Fecal microbiota transplantation (FMT) is increasingly supported by clinical trials as an effective treatment for recurrent Clostridium difficile infection, but a number of questions remain about how it can be optimally performed. In th...

Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection

BACKGROUND Fecal microbiota transplantation (FMT) has been shown to be safe and effective in treating refractory or relapsing C. difficile infection (CDI), but its use has been limited by practical barriers. We recently reported a small preliminary feasibility study using orally administered frozen fecal capsules. Following these early results, we now report our clinical experience in a large c...